- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Glenmark Launches Vancomycin Hydrochloride For Injection In 3 Doses | 239 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP... ► Artikel lesen | |
| GLENMARK PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Di | Glenmark launches Vancomycin Hydrochloride for injection USP in the USA | 4 | capitalmarket.com | ||
| 25.03. | Glenmark Pharmaceuticals Ltd: Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines | 247 | PR Newswire | MANILA, Philippines, March 25, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation... ► Artikel lesen | |
| 21.03. | Glenmark Pharma gains as arm gets USFDA nod for Olopatadine Ophthalmic solution | 3 | capitalmarket.com | ||
| 21.03. | Glenmark Gets FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) | 337 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its Olopatadine Hydrochloride Ophthalmic... ► Artikel lesen | |
| 21.03. | Stock Alert: Hindustan Unilever, Hindalco Inds, Glenmark Pharma, Ashoka Buildcon | 5 | capitalmarket.com | ||
| 12.03. | Glenmark Pharma launches generic Empagliflozin in India | 4 | capitalmarket.com | ||
| 10.03. | Glenmark Pharma launches osmotic laxative Polyethylene Glycol in US | 2 | capitalmarket.com | ||
| 04.03. | Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug | 10 | FiercePharma | ||
| 04.03. | Glenmark Pharma launches Acetylcysteine injection in US; long-term positive? | 6 | ZEE Business | ||
| 03.03. | Glenmark Acquires and Launches Acetylcysteine Injection | 2 | Contract Pharma | ||
| 03.03. | Glenmark Pharmaceuticals USA Buys, Launches Acetylcysteine Injection 6 Gm/30 ML Single-Dose Vials | 237 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA announces the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL Single-Dose Vials. The company acquired the ANDA for Acetylcysteine... ► Artikel lesen | |
| 03.03. | Glenmark Pharmaceuticals Ltd: Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials | 121 | PR Newswire | MAHWAH, N.J., March 3, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the acquisition and launch1 of Acetylcysteine Injection,... ► Artikel lesen | |
| 03.03. | Glenmark Pharma gains after arm launches Acetylcysteine injection | 3 | capitalmarket.com | ||
| 03.03. | Glenmark shares in focus after recall of 15 lakh bottles of ADHD drug in US | 4 | Times of India | ||
| 03.03. | Stocks in news: M&M, Glenmark Pharma, Tata Motors, IOB, Sun Pharma | 4 | Times of India | ||
| 27.02. | Glenmark Pharmaceuticals USA Launches Epinephrine Injection USP 10 Mg/10 ML Multiple-Dose Vial | 317 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Limited US, Thursday announced the launch of Epinephrine Injection USP, 10 mg/10 mL Multiple-Dose Vial.The company added that the newly launched... ► Artikel lesen | |
| 27.02. | Glenmark Pharma's US arm launches Epinephrine Injection USP, 10 mg/10 mL | 4 | capitalmarket.com | ||
| 24.02. | Glenmark to pay $7 million to settle lawsuits with three entities in US | 2 | ZEE Business | ||
| 24.02. | Glenmark Pharma gains on settling U.S. antitrust lawsuits for $7 million | 2 | capitalmarket.com |
Seite:
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SINOPHARM | 2,115 | -0,42 % | HTSC Trims SINOPHARM TP to $22.54 as 2024 NP Misses | ||
| CSPC PHARMA | 0,604 | -3,45 % | M Stanley Cuts CSPC PHARMA TP to $6.7, Rating Overweight | ||
| WUXI BIOLOGICS | 2,751 | -3,24 % | WUXI BIO (02269): (1) CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG; AND (2) DISCLOSEABLE TRANSACTION - COMPLETION OF THE ASSET TRANSACTION ... | ||
| SHANGHAI FOSUN PHARMACEUTICAL | 1,840 | +2,51 % | FOSUN PHARMA (02196): CONNECTED TRANSACTION - ENTERING INTO THE SHARE SUBSCRIPTION AGREEMENT | ||
| DR REDDYS | 11,300 | -3,42 % | Bio-Thera And Dr. Reddy's Partner To Launch Stelara And Simponi Biosimilars In Southeast Asia | NEW DELHI (dpa-AFX) - Bio-Thera Solutions and Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (RDY), announced that they have reached commercialization... ► Artikel lesen | |
| GEDEON RICHTER | 25,200 | -4,83 % | Gedeon Richter reicht Biosimilar RoActemra bei europäischer Behörde ein | ||
| ASPEN PHARMACARE | 7,650 | -1,29 % | Aspen Pharmacare Holdings reports 1H results | ||
| SHANGHAI PHARMACEUTICALS | 1,330 | +3,10 % | SH PHARMA (02607): FINAL DIVIDENDS FOR THE YEAR ENDED 31 DECEMBER 2024 | ||
| LUYE PHARMA | 0,250 | 0,00 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN JAPAN | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,072 | +0,70 % | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT - INJECTABLE POLYCAPROLACTONE MICROSPHERE FACIAL FILLER, SELF-DEVELOPED BY MEIYAN SPACE, OBTAINED REGISTRATION ... | ||
| CHINA RESOURCES PHARMACEUTICAL | 0,635 | +4,10 % | G Sachs Adds CHINARES PHARMA's TP to $6.17, Mildly Hikes Earnings Forecasts | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,885 | 0,00 % | SHINEWAY PHARM (02877): FIRST INTERIM DIVIDEND IN RESPECT OF THE FISCAL YEAR 2025 | ||
| HANSOH PHARMACEUTICAL | 2,640 | -4,35 % | HSI Up 244 pts; HSTI Up 97 pts; CSPC PHARMA Up over 12%; HANSOH PHARMA, CENTRAL NEW EGY, AKESO, LAOPU GOLD, 3SBIO Hit New Highs | ||
| KALBE FARMA | 0,057 | +0,89 % | KLBF potentially distribute 45% to 55% dividend for 2024: KLBF has the potential to distribute 45% to ... | ||
| YICHANG HEC CHANGJIANG PHARMACEUTICAL | - | - | HEC CJ PHARM (01558): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 |
GLENMARK PHARMACEUTICALS LIMITED gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLENMARK PHARMACEUTICALS LIMITED finden Sie auf Wallstreet Online.
